Többszörösen elo{combining double acute accent}kezelt, irinotecan-rezisztens kolorektális karcinómában szenvedo{combining double acute accent} beteg cetuximab terápiá jának eredményei

Translated title of the contribution: The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer

István Sipocz, J. Kulka, T. Pintér

Research output: Contribution to journalArticle

Abstract

Aim: The case of a patient with heavily pretreated, irinotecan-resistant, metastatic colorectal cancer is presented by the authors, and they would like to point to the effectiveness of a new therapeutic option, cetuximab treatment. Additionally, they would like to call attention to the need of performing EGFR determination from all of the biopsy samples (primary tumor, lymph nodes and metastases) to start the treatment. A weak EGFR-positivity of the primary tumor in fact does not mean the contraindication of cetuximab treatment, since the metastases, which are usually treated, could be strongly positive. The therapeutic answer could be excellent in this case, as it occurred in our case.

Original languageHungarian
Pages (from-to)337-342
Number of pages6
JournalMagyar Onkologia
Volume49
Issue number4
Publication statusPublished - 2005

Fingerprint

irinotecan
Colorectal Neoplasms
Neoplasm Metastasis
Therapeutics
Neoplasms
Lymph Nodes
Cetuximab
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{b5af984e74de4d21ab6c5b319feddf66,
title = "T{\"o}bbsz{\"o}r{\"o}sen elo{combining double acute accent}kezelt, irinotecan-rezisztens kolorekt{\'a}lis karcin{\'o}m{\'a}ban szenvedo{combining double acute accent} beteg cetuximab ter{\'a}pi{\'a} j{\'a}nak eredm{\'e}nyei",
abstract = "Aim: The case of a patient with heavily pretreated, irinotecan-resistant, metastatic colorectal cancer is presented by the authors, and they would like to point to the effectiveness of a new therapeutic option, cetuximab treatment. Additionally, they would like to call attention to the need of performing EGFR determination from all of the biopsy samples (primary tumor, lymph nodes and metastases) to start the treatment. A weak EGFR-positivity of the primary tumor in fact does not mean the contraindication of cetuximab treatment, since the metastases, which are usually treated, could be strongly positive. The therapeutic answer could be excellent in this case, as it occurred in our case.",
author = "Istv{\'a}n Sipocz and J. Kulka and T. Pint{\'e}r",
year = "2005",
language = "Hungarian",
volume = "49",
pages = "337--342",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Többszörösen elo{combining double acute accent}kezelt, irinotecan-rezisztens kolorektális karcinómában szenvedo{combining double acute accent} beteg cetuximab terápiá jának eredményei

AU - Sipocz, István

AU - Kulka, J.

AU - Pintér, T.

PY - 2005

Y1 - 2005

N2 - Aim: The case of a patient with heavily pretreated, irinotecan-resistant, metastatic colorectal cancer is presented by the authors, and they would like to point to the effectiveness of a new therapeutic option, cetuximab treatment. Additionally, they would like to call attention to the need of performing EGFR determination from all of the biopsy samples (primary tumor, lymph nodes and metastases) to start the treatment. A weak EGFR-positivity of the primary tumor in fact does not mean the contraindication of cetuximab treatment, since the metastases, which are usually treated, could be strongly positive. The therapeutic answer could be excellent in this case, as it occurred in our case.

AB - Aim: The case of a patient with heavily pretreated, irinotecan-resistant, metastatic colorectal cancer is presented by the authors, and they would like to point to the effectiveness of a new therapeutic option, cetuximab treatment. Additionally, they would like to call attention to the need of performing EGFR determination from all of the biopsy samples (primary tumor, lymph nodes and metastases) to start the treatment. A weak EGFR-positivity of the primary tumor in fact does not mean the contraindication of cetuximab treatment, since the metastases, which are usually treated, could be strongly positive. The therapeutic answer could be excellent in this case, as it occurred in our case.

UR - http://www.scopus.com/inward/record.url?scp=33645926030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645926030&partnerID=8YFLogxK

M3 - Article

C2 - 16518479

AN - SCOPUS:33645926030

VL - 49

SP - 337

EP - 342

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -